EE200200439A - Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest - Google Patents

Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest

Info

Publication number
EE200200439A
EE200200439A EEP200200439A EEP200200439A EE200200439A EE 200200439 A EE200200439 A EE 200200439A EE P200200439 A EEP200200439 A EE P200200439A EE P200200439 A EEP200200439 A EE P200200439A EE 200200439 A EE200200439 A EE 200200439A
Authority
EE
Estonia
Prior art keywords
production
receptor antagonist
pharmaceutical products
cannabinoid receptor
central cannabinoid
Prior art date
Application number
EEP200200439A
Other languages
English (en)
Inventor
Charles Blanchard Jean
Menard Fran�ois
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200200439A publication Critical patent/EE200200439A/et
Publication of EE04836B1 publication Critical patent/EE04836B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200439A 2000-02-09 2001-02-07 N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest EE04836B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
EE200200439A true EE200200439A (et) 2003-12-15
EE04836B1 EE04836B1 (et) 2007-06-15

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200439A EE04836B1 (et) 2000-02-09 2001-02-07 N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest

Country Status (33)

Country Link
US (2) US6930122B2 (et)
EP (1) EP1257275B1 (et)
JP (2) JP2003522145A (et)
CN (1) CN1250220C (et)
AR (1) AR028505A1 (et)
AT (1) ATE292467T1 (et)
AU (1) AU781827B2 (et)
BG (2) BG110386A (et)
BR (1) BR0108126A (et)
CA (1) CA2397262C (et)
CZ (1) CZ296685B6 (et)
DE (1) DE60109903T2 (et)
DK (1) DK1257275T3 (et)
EE (1) EE04836B1 (et)
ES (1) ES2240416T3 (et)
FR (1) FR2804604B1 (et)
HK (1) HK1051140A1 (et)
HU (1) HU225328B1 (et)
IL (1) IL150710A0 (et)
IS (1) IS6450A (et)
MX (1) MXPA02007766A (et)
NO (1) NO324521B1 (et)
NZ (1) NZ519924A (et)
PL (1) PL201685B1 (et)
PT (1) PT1257275E (et)
RS (1) RS50404B (et)
RU (1) RU2257207C2 (et)
SI (1) SI1257275T1 (et)
SK (1) SK284952B6 (et)
TW (1) TWI243677B (et)
UA (1) UA72783C2 (et)
WO (1) WO2001058450A2 (et)
ZA (1) ZA200205317B (et)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP5009488B2 (ja) 2001-08-13 2012-08-22 フィニサー コーポレイション 電子デバイスのウェハレベルバーンイン用システム
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
CA2479618A1 (en) 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CN1809552A (zh) * 2003-05-20 2006-07-26 田纳西大学研究基金会 大麻素衍生物、其制备方法和用途
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1682494A4 (en) * 2003-10-30 2006-11-08 Merck & Co Inc ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS
BRPI0513104A (pt) 2004-07-12 2008-04-29 Cadila Healthcare Ltd composto, composição farmacêutica, método para o tratamento de doenças associadas com os receptores de canabinóide, medicamento para o tratamento/redução de doenças associadas com os receptores de canabinóides, uso do composto, processo para a preparação do composto e intermediário
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
EP1973877A2 (en) * 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
JP2003522145A (ja) 2003-07-22
DE60109903D1 (de) 2005-05-12
RS50404B (sr) 2009-12-31
BG106946A (bg) 2003-05-30
UA72783C2 (en) 2005-04-15
PL358221A1 (en) 2004-08-09
SK284952B6 (sk) 2006-03-02
TWI243677B (en) 2005-11-21
IS6450A (is) 2002-06-28
IL150710A0 (en) 2003-02-12
EP1257275A2 (fr) 2002-11-20
MXPA02007766A (es) 2002-10-11
CA2397262A1 (en) 2001-08-16
HU225328B1 (en) 2006-09-28
US6930122B2 (en) 2005-08-16
CN1406128A (zh) 2003-03-26
PT1257275E (pt) 2005-07-29
DK1257275T3 (da) 2005-08-08
RU2002118309A (ru) 2004-02-20
CN1250220C (zh) 2006-04-12
BG65856B1 (bg) 2010-03-31
AU781827B2 (en) 2005-06-16
HK1051140A1 (en) 2003-07-25
CA2397262C (en) 2007-09-11
PL201685B1 (pl) 2009-04-30
BG110386A (en) 2009-09-30
SI1257275T1 (en) 2005-10-31
EE04836B1 (et) 2007-06-15
EP1257275B1 (fr) 2005-04-06
US20050187253A1 (en) 2005-08-25
NO324521B1 (no) 2007-11-12
DE60109903T2 (de) 2006-02-09
AU3562001A (en) 2001-08-20
RU2257207C2 (ru) 2005-07-27
ATE292467T1 (de) 2005-04-15
CZ20022698A3 (cs) 2002-11-13
HUP0300237A2 (hu) 2003-07-28
YU59002A (sh) 2005-07-19
ZA200205317B (en) 2003-09-04
FR2804604A1 (fr) 2001-08-10
HUP0300237A3 (en) 2003-09-29
WO2001058450A3 (fr) 2002-04-25
AR028505A1 (es) 2003-05-14
CZ296685B6 (cs) 2006-05-17
NO20023765L (no) 2002-10-09
FR2804604B1 (fr) 2005-05-27
NZ519924A (en) 2005-01-28
BR0108126A (pt) 2003-01-28
NO20023765D0 (no) 2002-08-08
ES2240416T3 (es) 2005-10-16
US20030087933A1 (en) 2003-05-08
JP2010018622A (ja) 2010-01-28
WO2001058450A2 (fr) 2001-08-16
SK11292002A3 (sk) 2003-02-04

Similar Documents

Publication Publication Date Title
EE200200439A (et) Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest
MA27366A1 (fr) Nouveaux derives de thiophenylglycoside, methodes pour leur production, medicaments contenant lesdits composes et leur utilisation
MA26903A1 (fr) Production continue de granules pharmaceutiques
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
HUP0302167A3 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
IS6002A (is) Pýrazólkarboxýlsýruafleiður, framleiðsla þeirra, lyfjasamsetningar sem innihalda þær
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
IS6811A (is) Lyfjafræðilegar samsetningar NMDA viðtakagerandefna
NO20032773L (no) Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater
EE200300245A (et) Bensotiofeeni derivaadid, nende valmistamise meetod ja kasutamine
TW200700062A (en) Pharmaceutical compositions
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
DK1960387T3 (da) Isoquinolin- og benzo[h]isoquinolinderivater, fremstilling deraf og terapeutisk anvendelse deraf som antagonister af histamin H3-receptoren
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
HUP0303127A3 (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
MXPA02009210A (es) Modificacion amorfa de torasemida.
FR2847254B1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
IS2441B (is) Notkun á pýridóindólon afleiðum til framleiðslu lyfja gegn krabbameini

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100207